Browse the latest SEC filings and forms submitted by GSK plc (GSK). Access annual reports, quarterly statements, and other official disclosures.
View Insider Transactions for GSK plc (GSK).
Search Company Filings →| Form | Filing Date | Description | Link |
|---|---|---|---|
| 6-K | March 30, 2026 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | March 30, 2026 | BEPIROVIRSEN ACCEPTED FOR REVIEW IN CHINA | View Document |
| 6-K | March 30, 2026 | EXDENSUR APPROVED FOR SEVERE ASTHMA IN CHINA | View Document |
| 6-K | March 27, 2026 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | March 27, 2026 | BEPIROVIRSEN ACCEPTED FOR REVIEW BY THE EMA | View Document |
| 6-K | March 26, 2026 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | March 25, 2026 | NOTICE OF AGM | View Document |
| 6-K | March 25, 2026 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 25, 2026 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | March 24, 2026 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | March 23, 2026 | GSK LUNG CANCER ADC GETS JAPAN ORPHAN DRUG STATUS | View Document |
| 6-K | March 23, 2026 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 23, 2026 | ADMISSION TO TRADING | View Document |
| 6-K | March 23, 2026 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | March 20, 2026 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | March 19, 2026 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | March 19, 2026 | LYNAVOY (LINERIXIBAT) APPROVED BY US FDA | View Document |
| 6-K | March 18, 2026 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 18, 2026 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | March 17, 2026 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 17, 2026 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | March 16, 2026 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | March 13, 2026 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | March 13, 2026 | US FDA APPROVES AREXVY FOR ADULTS 18-49 AIR | View Document |
| 6-K | March 12, 2026 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | March 12, 2026 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 11, 2026 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | March 10, 2026 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | March 9, 2026 | GSK AND ALFASIGMA AGREE GLOBAL LINERIXIBAT RIGHTS | View Document |
| 6-K | March 9, 2026 | BOARD COMMITTEE CHANGE | View Document |
| 6-K | March 9, 2026 | TRANSACTION IN OWN SHARES | View Document |
| 20-F | March 6, 2026 | 20-F | View Document |
| IRANNOTICE | March 6, 2026 | IRANNOTICE | View Document |
| 6-K | March 6, 2026 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | March 6, 2026 | FILING OF GSK PLC 2025 ANNUAL REPORT ON FORM 20-F | View Document |
| 6-K | March 5, 2026 | GSK PUBLISHES ANNUAL REPORT 2025 | View Document |
| 6-K | March 5, 2026 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | March 4, 2026 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | March 4, 2026 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 3, 2026 | GSK COMPLETES ACQUISITION OF RAPT THERAPEUTICS | View Document |
| 6-K | March 3, 2026 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | March 2, 2026 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | March 2, 2026 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Feb. 27, 2026 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Feb. 27, 2026 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 26, 2026 | BEPIROVIRSEN ACCEPTED FOR JAPAN REGULATORY REVIEW | View Document |
| 6-K | Feb. 26, 2026 | LINERIXIBAT ACCEPTED FOR PRIORITY REVIEW IN CHINA | View Document |
| 6-K | Feb. 26, 2026 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Feb. 25, 2026 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 25, 2026 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Feb. 25, 2026 | GSK ENTERS AGREEMENT TO ACQUIRE 35PHARMA | View Document |
| 6-K | Feb. 25, 2026 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 24, 2026 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 24, 2026 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Feb. 23, 2026 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Feb. 20, 2026 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Feb. 20, 2026 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 19, 2026 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Feb. 19, 2026 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 18, 2026 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Feb. 17, 2026 | GSK - FOURTH TRANCHE OF SHARE BUYBACK PROGRAMME | View Document |
| 6-K | Feb. 17, 2026 | EXDENSUR APPROVED BY THE EUROPEAN COMMISSION | View Document |
| 6-K | Feb. 17, 2026 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 17, 2026 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 17, 2026 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 17, 2026 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 17, 2026 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 13F-HR | Feb. 12, 2026 | - | View Document |
| 6-K | Feb. 11, 2026 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 11, 2026 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 11, 2026 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 11, 2026 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 10, 2026 | CHINA CDE ACCEPTS AREXVY ADULTS 60+ APPLICATION | View Document |
| 6-K | Feb. 9, 2026 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 6, 2026 | NUCALA COPD APPROVED BY THE EUROPEAN COMMISSION | View Document |
| 6-K | Feb. 6, 2026 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 5, 2026 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 4, 2026 | FINAL RESULTS | View Document |
| 6-K | Feb. 2, 2026 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Jan. 26, 2026 | EUROPEAN COMMISSION APPROVES AREXVY FOR ADULTS 18+ | View Document |
| 6-K | Jan. 20, 2026 | GSK TO ACQUIRE RAPT THERAPEUTICS | View Document |
| 6-K | Jan. 20, 2026 | AGREEMENT ON CHANGES TO VIIV MINORITY SHAREHOLDING | View Document |
| 6-K | Jan. 16, 2026 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Jan. 15, 2026 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Jan. 13, 2026 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Jan. 7, 2026 | EC APPROVAL OF SHINGRIX PFS | View Document |
| 6-K | Jan. 7, 2026 | POSITIVE PHASE 3 DATA FOR GSK'S BEPIROVIRSEN | View Document |
| 6-K | Jan. 6, 2026 | EXDENSUR APPROVED IN JAPAN | View Document |
| 6-K | Jan. 5, 2026 | NUCALA FOR ADULTS WITH COPD APPROVED IN CHINA | View Document |
| 6-K | Jan. 5, 2026 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Jan. 5, 2026 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Dec. 23, 2025 | GSK TO LOWER DRUG PRICES AND EXPAND ACCESS IN US | View Document |
| 6-K | Dec. 22, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Dec. 22, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Dec. 19, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Dec. 18, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Dec. 17, 2025 | EXDENSUR (DEPEMOKIMAB ULLA) APPROVED BY US FDA | View Document |
| 6-K | Dec. 17, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Dec. 16, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Dec. 16, 2025 | EXDENSUR (DEPEMOKIMAB) UK MHRA APPROVAL | View Document |
| 4 | Dec. 15, 2025 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP | View Document |
| 6-K | Dec. 15, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Dec. 12, 2025 | NUCALA RECEIVES POSITIVE CHMP OPINION FOR COPD | View Document |
| 6-K | Dec. 12, 2025 | POSITIVE CHMP OPINION ON AREXVY FOR ALL ADULTS 18+ | View Document |
| 6-K | Dec. 12, 2025 | DEPEMOKIMAB RECEIVES POSITIVE CHMP OPINION | View Document |
| 6-K | Dec. 12, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Dec. 11, 2025 | BLUJEPA APPROVED IN US FOR GONORRHOEA INDICATION | View Document |
| 6-K | Dec. 11, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Dec. 11, 2025 | BLOCK LISTING APPLICATION | View Document |
| 6-K | Dec. 11, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Dec. 10, 2025 | GSK'227 US FDA ORPHAN DRUG DESIGNATION IN SCLC | View Document |
| 6-K | Dec. 10, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Dec. 9, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Dec. 9, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Dec. 8, 2025 | TRANSACTION IN OWN SHARES | View Document |
| SCHEDULE 13D/A | Dec. 5, 2025 | - | View Document |
| 6-K | Dec. 5, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Dec. 4, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Dec. 3, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Dec. 2, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Dec. 1, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Dec. 1, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Dec. 1, 2025 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Nov. 28, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Nov. 28, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Nov. 26, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Nov. 25, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Nov. 24, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Nov. 21, 2025 | INITIATION OF LITIGATION AGAINST ANAPTYSBIO INC | View Document |
| 6-K | Nov. 21, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Nov. 20, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Nov. 19, 2025 | TRANSFER OF TREASURY SHARES | View Document |
| 6-K | Nov. 19, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Nov. 18, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Nov. 18, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Nov. 17, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Nov. 14, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Nov. 13, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Nov. 13, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Nov. 12, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Nov. 12, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Nov. 12, 2025 | BLOCK LISTING INTERIM REVIEW | View Document |
| 6-K | Nov. 10, 2025 | GSK PUBLISHES PROVISIONAL DIVIDEND DATES | View Document |
| 6-K | Nov. 10, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Nov. 7, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Nov. 6, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Nov. 5, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Nov. 4, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Nov. 3, 2025 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Nov. 3, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Oct. 31, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Oct. 30, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Oct. 30, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Oct. 29, 2025 | 3RD QUARTER RESULTS | View Document |
| 6-K | Oct. 29, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Oct. 28, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Oct. 28, 2025 | GSK ADC GETS ORPHAN DRUG DESIGNATION IN THE EU | View Document |
| 6-K | Oct. 27, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Oct. 24, 2025 | BLENREP APPROVED BY US FDA IN MULTIPLE MYELOMA | View Document |
| 6-K | Oct. 24, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Oct. 23, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Oct. 22, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Oct. 22, 2025 | POSITIVE DATA FOR LOW CARBON VERSION VENTOLIN MDI | View Document |
| 6-K | Oct. 22, 2025 | LATOZINEMAB DATA READ OUT | View Document |
| 6-K | Oct. 21, 2025 | POSITIVE CHMP OPINION FOR GSK ON SHINGRIX PFS | View Document |
| 6-K | Oct. 21, 2025 | GSK SHARE POSITIVE PH3 DATA ON TEBIPENEM HBR | View Document |
| 6-K | Oct. 21, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Oct. 20, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Oct. 17, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Oct. 16, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Oct. 16, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Oct. 15, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Oct. 15, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Oct. 14, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Oct. 14, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Oct. 14, 2025 | GSK RECEIVES EXPANDED SHINGRIX APPROVAL IN CHINA | View Document |
| 6-K | Oct. 14, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Oct. 10, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Oct. 10, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Oct. 9, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Oct. 8, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Oct. 7, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Oct. 6, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Oct. 3, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Oct. 2, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Oct. 1, 2025 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Oct. 1, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Sept. 30, 2025 | GSK - THIRD TRANCHE OF SHARE BUYBACK PROGRAMME | View Document |
| 6-K | Sept. 29, 2025 | GSK APPOINTS CEO DESIGNATE | View Document |
| 6-K | Sept. 22, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Sept. 19, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Sept. 18, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Sept. 17, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Sept. 17, 2025 | GSK US INVESTMENT ANNOUNCEMENT | View Document |
| 6-K | Sept. 16, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Sept. 15, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Sept. 12, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Sept. 11, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Sept. 10, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Sept. 10, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Sept. 9, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Sept. 8, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Sept. 5, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Sept. 4, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Sept. 4, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Sept. 3, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Sept. 2, 2025 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Sept. 2, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Sept. 2, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Aug. 29, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Aug. 28, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Aug. 27, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Aug. 26, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Aug. 22, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Aug. 21, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Aug. 21, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Aug. 20, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Aug. 19, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Aug. 19, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Aug. 18, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Aug. 15, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Aug. 14, 2025 | TRANSACTION IN OWN SHARES | View Document |
| SCHEDULE 13D | Aug. 13, 2025 | - | View Document |
| 6-K | Aug. 13, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Aug. 12, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Aug. 12, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Aug. 11, 2025 | FDA TO REVIEW GONORRHEA INDICATION FOR GEPOTIDACIN | View Document |
| 6-K | Aug. 11, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Aug. 8, 2025 | CUREVAC/BIONTECH MRNA PATENT LITIGATION SETTLEMENT | View Document |
| 6-K | Aug. 8, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Aug. 7, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Aug. 6, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Aug. 5, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Aug. 4, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Aug. 1, 2025 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Aug. 1, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | July 31, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | July 30, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | July 30, 2025 | 2ND QUARTER RESULTS | View Document |
| 6-K | July 29, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | July 28, 2025 | GSK ENTERS HENGRUI PHARMA COLLABORATION AGREEMENTS | View Document |
| 6-K | July 28, 2025 | PRIMARY DOCUMENT | View Document |
| 6-K | July 25, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | July 24, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | July 24, 2025 | BLENREP APPROVED IN THE EU FOR MULTIPLE MYELOMA | View Document |
| 6-K | July 23, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | July 23, 2025 | US FDA REVIEW EXTENDED FOR BLENREP | View Document |
| 6-K | July 22, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | July 21, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | July 18, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | July 18, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | July 18, 2025 | BLENREP US ODAC OUTCOME | View Document |
| 6-K | July 17, 2025 | GSKS SHINGRIX FULLY LIQUID FDA APPROVAL | View Document |
| 6-K | July 17, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | July 16, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | July 15, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | July 15, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | July 14, 2025 | GSK SUBMITS AREXVY FOR ADULTS 18-49 AIR TO FDA | View Document |
| 6-K | July 14, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | July 14, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | July 11, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | July 10, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | July 9, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | July 8, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | July 7, 2025 | GSK COMPLETES ACQUISITION OF EFIMOSFERMIN FOR SLD | View Document |
| 6-K | July 7, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | July 7, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | July 3, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | July 2, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | July 1, 2025 | TOTAL VOTING RIGHTS | View Document |
| 6-K | July 1, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | June 30, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | June 27, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | June 26, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | June 25, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | June 24, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | June 24, 2025 | DIRECTOR DECLARATION | View Document |
| 6-K | June 24, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | June 23, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | June 23, 2025 | LINERIXIBAT FILE ACCEPTED BY EMA | View Document |
| 6-K | June 23, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | June 20, 2025 | AREXVY FILED IN JAPAN FOR 18-49 AT INCREASED RISK | View Document |
| 6-K | June 20, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | June 20, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 11-K | June 18, 2025 | ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE | View Document |
| 11-K | June 18, 2025 | ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE PLANS | View Document |
| 6-K | June 18, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | June 17, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | June 16, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | June 13, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | June 13, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | June 13, 2025 | GSK SUBMITS AREXVY FOR ADULTS 18+ WITH EMA | View Document |
| 6-K | June 12, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | June 12, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | June 11, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | June 11, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | June 10, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | June 9, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | June 6, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | June 5, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | June 4, 2025 | GSK - SECOND TRANCHE OF SHARE BUYBACK PROGRAMME | View Document |
| 6-K | June 4, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | June 3, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | June 2, 2025 | TOTAL VOTING RIGHTS | View Document |
| 6-K | June 2, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | June 2, 2025 | LINERIXIBAT FILE ACCEPTED FOR REVIEW BY US FDA | View Document |
| 6-K | June 2, 2025 | TRANSACTION IN OWN SHARES | View Document |
| SD | May 30, 2025 | SPECIALIZED DISCLOSURE REPORT | View Document |
| 6-K | May 30, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | May 29, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | May 28, 2025 | GSK STOPS PHASE 3 TRIAL ON CUTIS FOR EFFICACY | View Document |
| 6-K | May 28, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | May 27, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | May 23, 2025 | FDA APPROVES NUCALA COPD INDICATION | View Document |
| 6-K | May 23, 2025 | POSITIVE CHMP OPINION ON BLENREP IN EU | View Document |
| 6-K | May 23, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | May 22, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | May 21, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | May 20, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | May 20, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | May 19, 2025 | BLENREP FOR 2L+ MULTIPLE MYELOMA APPROVED IN JAPAN | View Document |
| 6-K | May 19, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | May 16, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 25-NSE | May 15, 2025 | - | View Document |
| 6-K | May 15, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | May 14, 2025 | GSK TO ACQUIRE EFIMOSFERMIN | View Document |
| 6-K | May 14, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | May 13, 2025 | UPDATE ON BELRESTOTUG DEVELOPMENT PROGRAMME | View Document |
| 6-K | May 13, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | May 13, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | May 12, 2025 | BLOCK LISTING INTERIM REVIEW | View Document |
| 6-K | May 12, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | May 9, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | May 8, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | May 8, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | May 8, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | May 8, 2025 | LINERIXIBAT GLISTEN PIII TRIAL DATA AT EASL | View Document |
| 6-K | May 7, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | May 7, 2025 | RESULT OF AGM | View Document |
| 6-K | May 6, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | May 2, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | May 1, 2025 | NUCALA MATINEE DATA IN COPD PUBLISHED IN NEJM | View Document |
| 6-K | May 1, 2025 | TOTAL VOTING RIGHTS | View Document |
| 6-K | May 1, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | May 1, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | April 30, 2025 | 1ST QUARTER RESULTS | View Document |
| 6-K | April 30, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | April 29, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | April 28, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | April 25, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | April 24, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | April 23, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | April 22, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | April 17, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | April 17, 2025 | BLENREP LICENSED BY UK MHRA | View Document |
| 6-K | April 17, 2025 | GSK 5-IN-1 MENINGITIS VACCINE RECOMMENDED IN US | View Document |
| 6-K | April 17, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | April 17, 2025 | AREXVY NOW ACIP RECOMMENDED FOR 50-59 AT RIS | View Document |
| 6-K | April 16, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | April 15, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | April 15, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | April 14, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | April 14, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | April 11, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | April 11, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | April 10, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | April 9, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | April 8, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | April 7, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | April 4, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | April 3, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | April 2, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | April 1, 2025 | TOTAL VOTING RIGHTS | View Document |
| 6-K | April 1, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | March 31, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | March 28, 2025 | TRANSACTION IN OWN SHARES | View Document |
| SCHEDULE 13D/A | March 28, 2025 | - | View Document |
| 6-K | March 28, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 27, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | March 26, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | March 25, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | March 25, 2025 | GSK UUTI TREATMENT APPROVED BY US FDA | View Document |
| 6-K | March 24, 2025 | EMA FILING ACCEPTANCE FOR NUCALA COPD | View Document |
| 6-K | March 24, 2025 | NOTICE OF AGM | View Document |
| 6-K | March 24, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | March 21, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 21, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | March 20, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | March 19, 2025 | TRANSACTION IN OWN SHARES | View Document |
| CERT | March 18, 2025 | NYSE CERTIFICATION | View Document |
| CERT | March 18, 2025 | NYSE CERTIFICATION | View Document |
| 6-K | March 18, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | March 17, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | March 14, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 14, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | March 13, 2025 | 6-K | View Document |
| 6-K | March 13, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 8-A12B | March 13, 2025 | 8-A12B | View Document |
| 8-A12B | March 13, 2025 | 8-A12B | View Document |
| 6-K | March 12, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | March 11, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 424B2 | March 10, 2025 | 424B2 | View Document |
| 6-K | March 10, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | March 7, 2025 | TRANSACTION IN OWN SHARES | View Document |
| SCHEDULE 13G/A | March 7, 2025 | - | View Document |
| FWP | March 7, 2025 | FWP | View Document |
| 6-K | March 6, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 424B2 | March 6, 2025 | 424B2 | View Document |
| 6-K | March 5, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | March 4, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 20-F | March 3, 2025 | 20-F | View Document |
| 6-K | March 3, 2025 | US FDA ACCEPT 2 DEPEMOKIMAB INDICATION SUBMISSIONS | View Document |
| 6-K | March 3, 2025 | GSK PLC 2024 ANNUAL REPORT ON FORM 20-F | View Document |
| IRANNOTICE | March 3, 2025 | IRANNOTICE | View Document |
| 6-K | March 3, 2025 | TOTAL VOTING RIGHTS | View Document |
| 6-K | March 3, 2025 | ANCHOR RESULTS PRESENTED AT 2025 AAAAI | View Document |
| 6-K | March 3, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Feb. 28, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Feb. 27, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Feb. 27, 2025 | GSK PUBLISHES ANNUAL REPORT 2024 | View Document |
| 6-K | Feb. 26, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 26, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Feb. 25, 2025 | TRANSACTION IN OWN SHARES | View Document |
| 6-K | Feb. 24, 2025 | GSK COMPLETES ACQUISITION OF IDRX, INC. | View Document |
| 6-K | Feb. 24, 2025 | GSK PLC COMMENCES SHARE BUYBACK PROGRAMME | View Document |
| 6-K | Feb. 21, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 21, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 21, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 21, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 21, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 21, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 21, 2025 | DIRECTORATE CHANGE | View Document |
| 6-K | Feb. 20, 2025 | NUCALA COPD SUBMISSION ACCEPTED IN CHINA | View Document |
| 6-K | Feb. 18, 2025 | GSK 5-IN-1 MENINGITIS VACCINE APPROVED BY US FDA | View Document |
| 6-K | Feb. 13, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 11, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 5, 2025 | FINAL RESULTS | View Document |
| 6-K | Feb. 3, 2025 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Jan. 28, 2025 | EMA ACCEPTS TWO SUBMISSIONS FOR DEPEMOKIMAB | View Document |
| 6-K | Jan. 28, 2025 | DEPEMOKIMAB DUAL FILING IN CHINA AND JAPAN | View Document |
| 6-K | Jan. 27, 2025 | EMA ACCEPT REVIEW SHINGRIX SYRINGE PRESENTATION | View Document |
| 6-K | Jan. 21, 2025 | JEMPERLI EXPANDED APPROVAL IN THE EU | View Document |
| 6-K | Jan. 16, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Jan. 15, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Jan. 14, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Jan. 13, 2025 | GSK ENTERS AGREEMENT TO ACQUIRE IDRX, INC. | View Document |
| 6-K | Jan. 13, 2025 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Jan. 10, 2025 | SHINGRIX FULLY LIQUID ACCEPTED FOR US FDA REVIEW | View Document |
| 6-K | Jan. 7, 2025 | GSK ADC GETS FDA BREAKTHROUGH THERAPY DESIGNATION | View Document |
| 6-K | Jan. 3, 2025 | GSK'S NUCALA APPROVED IN CHINA FOR USE IN CRSWNP | View Document |
| 6-K | Jan. 2, 2025 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Dec. 23, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Dec. 20, 2024 | BLOCK LISTING APPLICATION | View Document |
| 6-K | Dec. 20, 2024 | HEADLINE RESULTS FROM PHASE III FIRST TRIAL | View Document |
| 6-K | Dec. 16, 2024 | JEMPERLI RECEIVES US FDA BREAKTHROUGH DESIGNATION | View Document |
| 6-K | Dec. 16, 2024 | EMA GRANTS PRIME DESIGNATION FOR GSK 227 | View Document |
| 6-K | Dec. 16, 2024 | JEMPERLI RECEIVES POSITIVE CHMP OPINION | View Document |
| 6-K | Dec. 12, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Dec. 9, 2024 | NUCALA COPD SUBMISSION ACCEPTED BY US FDA | View Document |
| 6-K | Dec. 9, 2024 | OVERALL SURVIVAL DATA PRESENTED FOR BLENREP | View Document |
| 6-K | Dec. 9, 2024 | BLENREP COMBINATION CHINA FILING ACCEPTANCE | View Document |
| 6-K | Dec. 5, 2024 | ZHIFEI CHINA COLLABORATION REVISED AND EXTENDED | View Document |
| 6-K | Dec. 2, 2024 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Dec. 2, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Nov. 27, 2024 | GSK LIQUID MENINGITIS VACCINE AUTHORISED IN EU | View Document |
| 6-K | Nov. 25, 2024 | BLENREP COMBINATIONS ACCEPTED FOR US FDA REVIEW | View Document |
| 6-K | Nov. 22, 2024 | JAPAN APPROVES FIRST RSV VACCINE FOR ADULTS 50-59 | View Document |
| 6-K | Nov. 19, 2024 | GLISTEN TRIAL OF LINERIXIBAT MEETS ENDPOINT | View Document |
| 6-K | Nov. 19, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| SC 13D/A | Nov. 15, 2024 | AMENDMENT TO THE SCHEDULE 13D | View Document |
| 6-K | Nov. 14, 2024 | GSK ANNOUNCES OVERALL SURVIVAL RESULTS FOR BLENREP | View Document |
| 6-K | Nov. 13, 2024 | BLOCK LISTING INTERIM REVIEW | View Document |
| 6-K | Nov. 12, 2024 | GSK PUBLISHES PROVISIONAL 2025 DIVIDEND DATES | View Document |
| SC 13G/A | Nov. 12, 2024 | AMENDMENT TO FORM SC 13G | View Document |
| 6-K | Nov. 12, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Nov. 1, 2024 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Oct. 30, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Oct. 30, 2024 | 3RD QUARTER RESULTS | View Document |
| 6-K | Oct. 24, 2024 | NEW POSITIVE AREXVY DATA IN YOUNGER ADULTS AT RISK | View Document |
| 6-K | Oct. 17, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Oct. 16, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Oct. 16, 2024 | FDA ACCEPTS NEW DRUG APPLICATION FOR GEPOTIDACIN | View Document |
| 6-K | Oct. 15, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Oct. 15, 2024 | POSITIVE RESULTS OF ANCHOR TRIALS OF DEPEMOKIMAB | View Document |
| 6-K | Oct. 11, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Oct. 10, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Oct. 9, 2024 | ZANTAC (RANITIDINE) LITIGATION SETTLEMENTS | View Document |
| 6-K | Oct. 8, 2024 | POSITIVE EFFICACY DATA OF AREXVY OVER 3 SEASONS | View Document |
| 4 | Oct. 1, 2024 | WVE - CHANGE IN BENEFICIAL OWNERSHIP | View Document |
| 6-K | Oct. 1, 2024 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Sept. 24, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Sept. 24, 2024 | POSITIVE EU OPINION FOR GSK LIQUID MENVEO VACCINE | View Document |
| 6-K | Sept. 18, 2024 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 6-K | Sept. 17, 2024 | JAPAN FILING ACCEPTANCE: BLENREP MULTIPLE MYELOMA | View Document |
| 6-K | Sept. 13, 2024 | CHINA BREAKTHROUGH THERAPY DESIGNATION FOR BLENREP | View Document |
| 6-K | Sept. 12, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Sept. 12, 2024 | POSITIVE MRNA FLU VACCINE PHASE II HEADLINE DATA | View Document |
| 6-K | Sept. 11, 2024 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 6-K | Sept. 11, 2024 | CHANGE OF REGISTERED OFFICE | View Document |
| 6-K | Sept. 11, 2024 | UPDATE ON PHASE I/II THERAPEUTIC HSV VACCINE TRIAL | View Document |
| 6-K | Sept. 9, 2024 | DEPEMOKIMAB LATE-BREAKING DATA PRESENTED AT ERS | View Document |
| 6-K | Sept. 6, 2024 | POSITIVE PHASE III RESULTS FOR NUCALA IN COPD | View Document |
| 6-K | Sept. 6, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Sept. 3, 2024 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Aug. 29, 2024 | EMA APPROVAL ON AREXVY FOR 50-59 AT RISK | View Document |
| 6-K | Aug. 28, 2024 | NUCALA APPROVED IN JAPAN FOR USE IN CRSWNP | View Document |
| 6-K | Aug. 28, 2024 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 6-K | Aug. 28, 2024 | SENKU DESIGNATION FOR BEPIROVIRSEN IN JAPAN | View Document |
| 6-K | Aug. 21, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Aug. 20, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Aug. 20, 2024 | B7-H3 ADC US FDA BREAKTHROUGH THERAPY DESIGNATION | View Document |
| 6-K | Aug. 16, 2024 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 6-K | Aug. 12, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Aug. 6, 2024 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 6-K | Aug. 2, 2024 | FDA EXPANDS JEMPERLI APPROVAL | View Document |
| 6-K | Aug. 1, 2024 | TOTAL VOTING RIGHTS | View Document |
| 6-K | July 31, 2024 | 2ND QUARTER RESULTS | View Document |
| 6-K | July 29, 2024 | CHMP POSITIVE OPINION ON AREXVY FOR 50-59 AT RISK | View Document |
| 6-K | July 29, 2024 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 6-K | July 19, 2024 | BLENREP EMA FILING ACCEPTANCE | View Document |
| 6-K | July 18, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | July 16, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | July 15, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | July 12, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | July 3, 2024 | GSK AND CUREVAC COLLABORATION RESTRUCTURED | View Document |
| 6-K | July 1, 2024 | TOTAL VOTING RIGHTS | View Document |
| 6-K | June 28, 2024 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 6-K | June 24, 2024 | EMA VALIDATES JEMPERLI MARKETING AUTHORISATION | View Document |
| 6-K | June 24, 2024 | OMJJARA APPROVED IN JAPAN FOR MYELOFIBROSIS | View Document |
| 6-K | June 21, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 11-K | June 18, 2024 | ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE | View Document |
| 11-K | June 18, 2024 | ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE | View Document |
| 6-K | June 12, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | June 11, 2024 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 6-K | June 10, 2024 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 6-K | June 10, 2024 | FDA APPROVES AREXVY FOR ADULTS 50-59 AT RISK | View Document |
| 6-K | June 3, 2024 | TOTAL VOTING RIGHTS | View Document |
| 6-K | June 3, 2024 | ASCO POSITIVE BLENREP DREAMM-8 TRIAL RESULTS | View Document |
| 6-K | June 3, 2024 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 25-NSE | June 3, 2024 | - | View Document |
| 6-K | June 3, 2024 | UNPRECEDENTED RESULTS IN JEMPERLI TRIAL CONTINUE | View Document |
| SD | May 31, 2024 | SPECIALIZED DISCLOSURE REPORT | View Document |
| 6-K | May 24, 2024 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 6-K | May 21, 2024 | POSITIVE PHASE III ASTHMA RESULTS FOR DEPEMOKIMAB | View Document |
| 6-K | May 20, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | May 17, 2024 | CURRENT REPORT | View Document |
| 6-K | May 17, 2024 | GSK COMPLETES SALE OF SHARES IN HALEON PLC | View Document |
| 6-K | May 14, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | May 13, 2024 | BLOCK LISTING INTERIM REVIEW | View Document |
| 6-K | May 8, 2024 | BOARD COMMITTEE CHANGE | View Document |
| 6-K | May 8, 2024 | RESULT OF AGM | View Document |
| 6-K | May 3, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | May 1, 2024 | TOTAL VOTING RIGHTS | View Document |
| 6-K | May 1, 2024 | 1ST QUARTER RESULTS | View Document |
| 6-K | April 24, 2024 | US FDA ACCEPTS NEW INDICATION FILING FOR JEMPERLI | View Document |
| 6-K | April 19, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | April 17, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | April 17, 2024 | RESULTS FROM LONG-TERM DATA RELATING TO SHINGRIX | View Document |
| 6-K | April 17, 2024 | GSK ANNOUNCES ADDITIONAL EAGLE-1 RESULTS | View Document |
| 6-K | April 16, 2024 | FDA ACCEPTS GSK MENINGITIS VACCINE CANDIDATE FILE | View Document |
| 6-K | April 16, 2024 | AMENDMENT - DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | April 15, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K/A | April 4, 2024 | REPLACEMENT - TOTAL VOTING RIGHTS | View Document |
| 6-K | April 2, 2024 | TOTAL VOTING RIGHTS | View Document |
| SC 13D/A | March 28, 2024 | AMENDMENT TO FORM SC 13D | View Document |
| 6-K | March 26, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| F-3ASR | March 25, 2024 | F-3ASR | View Document |
| 6-K | March 25, 2024 | NOTICE OF AGM | View Document |
| 6-K | March 22, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 22, 2024 | TRANSFER OF TREASURY SHARES | View Document |
| 6-K | March 18, 2024 | NEW PHASE III JEMPERLI DATA IN ENDOMETRIAL CANCER | View Document |
| 6-K | March 13, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 8, 2024 | BOARD COMMITTEE CHANGE | View Document |
| 6-K | March 7, 2024 | GSK ANNOUNCES POSITIVE BLENREP DREAMM-8 RESULTS | View Document |
| 6-K | March 6, 2024 | VIIV LAI VS ORAL SOC DATA IN ADHERENCE-CHALLENGED | View Document |
| 20-F | March 5, 2024 | 20-F | View Document |
| 6-K | March 5, 2024 | GSK ANNUAL REPORT 2023 ON FORM 20 F | View Document |
| IRANNOTICE | March 5, 2024 | IRANNOTICE | View Document |
| 6-K | March 5, 2024 | NEW VIIV LA FORMULATION POTENTIAL 4-MONTH DOSING | View Document |
| 6-K | March 1, 2024 | GSK PUBLISHES ANNUAL REPORT 2023 | View Document |
| 6-K | March 1, 2024 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Feb. 29, 2024 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 6-K | Feb. 29, 2024 | DIRECTORATE CHANGE | View Document |
| 6-K | Feb. 26, 2024 | GSK ANNOUNCES POSITIVE EAGLE-1 HEADLINE RESULTS | View Document |
| 6-K | Feb. 26, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 22, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 21, 2024 | VIIV LAI SUPERIOR TO ORALS IN ADHERENCE-CHALLENGED | View Document |
| 6-K | Feb. 20, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 15, 2024 | GSK COMPLETES ACQUISITION OF AIOLOS BIO | View Document |
| 6-K | Feb. 15, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 13, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 13, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| SC 13G/A | Feb. 13, 2024 | SC 13G/A | View Document |
| 6-K | Feb. 13, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 12, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 12, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 12, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 12, 2024 | US FDA FAST TRACK DESIGNATION FOR BEPIROVIRSEN | View Document |
| SC 13D/A | Feb. 9, 2024 | AMENDMENT TO SC 13D | View Document |
| 6-K | Feb. 6, 2024 | SHINGRIX 18+ AT RISK CHINA FILING REVIEW ACCEPTED | View Document |
| SC 13G/A | Feb. 6, 2024 | AMENDMENT TO FORM SC 13G | View Document |
| SC 13G/A | Feb. 6, 2024 | AMENDMENT TO FORM SC 13G | View Document |
| 6-K | Feb. 6, 2024 | FDA ACCEPTS AREXVY FILING FOR ADULTS 50-59 AT RISK | View Document |
| 6-K | Feb. 6, 2024 | GSK PRESENTS POSITIVE DREAMM-7 PHASE III DATA | View Document |
| 6-K | Feb. 1, 2024 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Feb. 1, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 1, 2024 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 6-K | Jan. 31, 2024 | FINAL RESULTS | View Document |
| 4 | Jan. 30, 2024 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP | View Document |
| 6-K | Jan. 29, 2024 | EUROPEAN COMMISSION AUTHORISES OMJJARA IN THE EU | View Document |
| 6-K | Jan. 29, 2024 | EMA ACCEPTS AREXVY FILING FOR ADULTS 50-59 AT RISK | View Document |
| SC 13D/A | Jan. 19, 2024 | AMENDMENT TO FORM SC 13D | View Document |
| 6-K | Jan. 19, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Jan. 17, 2024 | GSK COMPLETES SALE OF SHARES IN HALEON PLC | View Document |
| 6-K | Jan. 17, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Jan. 17, 2024 | CURRENT REPORT | View Document |
| 6-K | Jan. 16, 2024 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Jan. 10, 2024 | NUCALA APPROVED IN CHINA FOR USE IN SEVERE ASTHMA | View Document |
| 6-K | Jan. 9, 2024 | GSK ENTERS AGREEMENT TO ACQUIRE AIOLOS BIO | View Document |
| 6-K | Jan. 2, 2024 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Dec. 21, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Dec. 18, 2023 | JEMPERLI PLUS ZEJULA TRIAL MEETS ENDPOINT | View Document |
| 6-K | Dec. 13, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Dec. 12, 2023 | JAPAN ACCEPTS AREXVY FILING FOR AT RISK ADULTS | View Document |
| 6-K | Dec. 11, 2023 | JEMPERLI PLUS CHEMOTHERAPY EU AUTHORISATION | View Document |
| 6-K | Dec. 4, 2023 | GSK PUBLISHES PROVISIONAL 2024 DIVIDEND DATES | View Document |
| 6-K | Dec. 1, 2023 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Nov. 30, 2023 | BLOCK LISTING APPLICATION | View Document |
| 6-K | Nov. 29, 2023 | HOLDING(S) IN COMPANY | View Document |
| 6-K | Nov. 27, 2023 | GSK ANNOUNCES POSITIVE DREAMM-7 HEADLINE RESULTS | View Document |
| 6-K | Nov. 21, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Nov. 15, 2023 | BLOCK LISTING INTERIM REVIEW | View Document |
| 6-K | Nov. 13, 2023 | GSK RECEIVES POSITIVE CHMP OPINION FOR MOMELOTINIB | View Document |
| 6-K | Nov. 13, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Nov. 1, 2023 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Nov. 1, 2023 | 3RD QUARTER RESULTS | View Document |
| 6-K | Oct. 30, 2023 | JEMPERLI TRIAL MEETS OVERALL SURVIVAL ENDPOINT | View Document |
| 6-K | Oct. 26, 2023 | NMPA APPROVES VOCABRIA+REKAMBYS IN CHINA | View Document |
| 6-K | Oct. 25, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Oct. 25, 2023 | NEW DATA FOR AREXVY, GSK'S RSV VACCINE | View Document |
| 6-K | Oct. 20, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Oct. 18, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Oct. 17, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Oct. 16, 2023 | JEMPERLI PLUS CHEMOTHERAPY POSITIVE CHMP OPINION | View Document |
| 6-K | Oct. 13, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Oct. 12, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Oct. 11, 2023 | ZANTAC (RANITIDINE) LITIGATION | View Document |
| SC 13D/A | Oct. 10, 2023 | AMENDMENT TO FORM SC 13D | View Document |
| 6-K | Oct. 10, 2023 | GSK AND ZHIFEI ANNOUNCE VACCINE PARTNERSHIP | View Document |
| 6-K | Oct. 6, 2023 | CURRENT REPORT | View Document |
| 6-K | Oct. 6, 2023 | GSK COMPLETES SALE OF SHARES IN HALEON PLC | View Document |
| 25-NSE | Oct. 2, 2023 | - | View Document |
| 6-K | Oct. 2, 2023 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Sept. 27, 2023 | DIRECTORATE CHANGE | View Document |
| 6-K | Sept. 25, 2023 | GSK RSV VACCINE FOR OLDER ADULTS APPROVED IN JAPAN | View Document |
| 6-K | Sept. 21, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Sept. 19, 2023 | APRETUDE FOR PREP RECEIVES EMA APPROVAL | View Document |
| 6-K | Sept. 18, 2023 | FDA APPROVES OJJAARA (MOMELOTINIB) | View Document |
| 6-K | Sept. 13, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Sept. 11, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| SC 13D/A | Sept. 11, 2023 | AMENDMENT TO FORM SC 13D | View Document |
| 6-K | Sept. 11, 2023 | MOMELOTINIB FILING ACCEPTED IN JAPAN | View Document |
| 6-K | Sept. 6, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Sept. 1, 2023 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Sept. 1, 2023 | GSK'S NUCALA CRSWNP SUBMISSION ACCEPTED IN JAPAN | View Document |
| 6-K | Aug. 31, 2023 | HOLDING(S) IN COMPANY | View Document |
| 6-K | Aug. 31, 2023 | HOLDING(S) IN COMPANY | View Document |
| 6-K | Aug. 25, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Aug. 23, 2023 | SHINGRIX DATA DEMONSTRATE 100% EFFICACY IN CHINA | View Document |
| 6-K | Aug. 23, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Aug. 22, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Aug. 10, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Aug. 9, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Aug. 1, 2023 | TOTAL VOTING RIGHTS | View Document |
| 6-K | July 31, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | July 31, 2023 | FDA APPROVES NEW USE FOR JEMPERLI PLUS CHEMO | View Document |
| 6-K | July 28, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | July 26, 2023 | 2ND QUARTER RESULTS | View Document |
| 6-K | July 24, 2023 | CABOTEGRAVIR LA FOR PREP RECEIVES POSITIVE CHMP | View Document |
| SC 13D/A | July 20, 2023 | AMENDMENT TO FORM SC 13D | View Document |
| 6-K | July 20, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | July 17, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | July 13, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | July 3, 2023 | TOTAL VOTING RIGHTS | View Document |
| 6-K | June 28, 2023 | GSK COMPLETES ACQUISITION OF BELLUS HEALTH | View Document |
| 6-K | June 27, 2023 | FDA FAST TRACK FOR GONORRHOEA VACCINE CANDIDATE | View Document |
| 6-K | June 26, 2023 | GSK DAPRODUSTAT GAINS POSITIVE EMA CHMP OPINION | View Document |
| 6-K | June 26, 2023 | SHINGRIX APPROVED IN JAPAN FOR ADULTS 18 AND OVER | View Document |
| 6-K | June 23, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | June 23, 2023 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 6-K | June 23, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | June 23, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | June 22, 2023 | GSKS AREXVY RECOMMENDED BY ACIP | View Document |
| 6-K | June 21, 2023 | SEASON TWO DATA FOR GSK AREXVY RSV OA VACCINE | View Document |
| 11-K | June 21, 2023 | ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE | View Document |
| 11-K | June 21, 2023 | ANNUAL REPORT | View Document |
| 6-K | June 16, 2023 | EXTENSION OF FDA REVIEW PERIOD FOR MOMELOTINIB | View Document |
| 6-K | June 12, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | June 7, 2023 | EU AUTHORISATION OF GSKS RSV VACCINE AREXVY | View Document |
| 6-K | June 6, 2023 | GSK RECEIVES US FDA FILE ACCEPTANCE FOR JEMPERLI | View Document |
| 6-K | June 1, 2023 | TOTAL VOTING RIGHTS | View Document |
| SD | May 30, 2023 | SPECIALIZED DISCLOSURE | View Document |
| 6-K | May 22, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| SC 13D/A | May 16, 2023 | AMENDMENT TO FORM SC 13D | View Document |
| 6-K | May 15, 2023 | BLOCK LISTING INTERIM REVIEW | View Document |
| 6-K | May 15, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | May 12, 2023 | CURRENT REPORT OF FOREIGN ISSUER | View Document |
| 6-K | May 12, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | May 12, 2023 | MENABCWY VACCINE PRELIMINARY PHASE III RESULTS | View Document |
| 6-K | May 12, 2023 | STATEMENT: ZANTAC LITIGATION UPDATE BC CANADA | View Document |
| 6-K | May 12, 2023 | GSK COMPLETES SALE OF SHARES IN HALEON PLC | View Document |
| 6-K | May 9, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | May 4, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | May 3, 2023 | US FDA APPROVES GSKS RSV VACCINE FOR OLDER ADULTS | View Document |
| 6-K | May 3, 2023 | RESULT OF AGM | View Document |
| 6-K | May 2, 2023 | TOTAL VOTING RIGHTS | View Document |
| 6-K | April 28, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | April 27, 2023 | GSK RSV OA VACCINE GAINS POSITIVE EMA CHMP OPINION | View Document |
| 6-K | April 26, 2023 | 1ST QUARTER RESULTS | View Document |
| 6-K | April 25, 2023 | EMA VALIDATES JEMPERLI FILING FOR NEW INDICATION | View Document |
| 6-K | April 20, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | April 19, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | April 18, 2023 | GSK REACHES AGREEMENT TO ACQUIRE BELLUS HEALTH INC | View Document |
| 6-K | April 17, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 20-F/A | April 17, 2023 | 20-F/A | View Document |
| 6-K | April 17, 2023 | GEPOTIDACIN POSITIVE PHASE III DATA | View Document |
| 6-K | April 3, 2023 | TOTAL VOTING RIGHTS | View Document |
| 6-K | March 28, 2023 | POSITIVE PHASE III RUBY RESULTS FOR JEMPERLI | View Document |
| 6-K | March 27, 2023 | PUBLICATION OF 2023 AGM NOTICE | View Document |
| 6-K | March 24, 2023 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 6-K | March 21, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 20, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| EFFECT | March 15, 2023 | - | View Document |
| 6-K | March 14, 2023 | POSITIVE PHASE III RESULTS FOR MENABCWY VACCINE | View Document |
| 6-K | March 14, 2023 | NUCALA NDA ACCEPTED FOR REVIEW IN CHINA | View Document |
| 6-K | March 13, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 10, 2023 | GSK ANNUAL REPORT 2022 ON FORM 20-F | View Document |
| POS AM | March 10, 2023 | POS AM | View Document |
| IRANNOTICE | March 10, 2023 | IRANNOTICE | View Document |
| 6-K | March 10, 2023 | GSK PUBLISHES ANNUAL REPORT 2022 | View Document |
| 20-F | March 10, 2023 | 20-F | View Document |
| 6-K | March 2, 2023 | FDA AD COM VOTES TO SUPPORT GSK RSV OA VACCINE | View Document |
| 6-K | March 1, 2023 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Feb. 27, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 23, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 23, 2023 | VIIV HEALTHCARE ANNOUNCES CABENUVA POSITIVE DATA | View Document |
| 6-K | Feb. 22, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 16, 2023 | NEJM PUBLISHES GSK RSV OA VACCINE CANDIDATE TRIAL | View Document |
| 6-K | Feb. 15, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 15, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| SC 13G/A | Feb. 14, 2023 | SC 13G/A | View Document |
| 6-K | Feb. 14, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 14, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 14, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 14, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 10, 2023 | JEMPERLI FDA ODAC POSITIVE OUTCOME | View Document |
| 6-K | Feb. 10, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 10, 2023 | JEMPERLI FULL FDA APPROVAL FOLLOWING GARNET TRIAL | View Document |
| SC 13G | Feb. 6, 2023 | SCHEDULE 13G | View Document |
| 6-K | Feb. 2, 2023 | DAPRODUSTAT APPROVED BY US FDA FOR ANAEMIA OF CKD | View Document |
| 6-K | Feb. 1, 2023 | BENLYSTA GRANTED ORPHAN DRUG DESIGNATION BY US FDA | View Document |
| 6-K | Feb. 1, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 1, 2023 | FINAL RESULTS | View Document |
| 6-K | Feb. 1, 2023 | TOTAL VOTING RIGHTS | View Document |
| SC 13G | Jan. 30, 2023 | SCHEDULE 13G | View Document |
| 3 | Jan. 30, 2023 | INITIAL STATEMENT OF BENEFICIAL OWNERSHIP | View Document |
| SC 13D/A | Jan. 20, 2023 | SCHEDULE 13D/A | View Document |
| SC 13D/A | Jan. 20, 2023 | AMENDMENT TO FORM SC 13D | View Document |
| 6-K | Jan. 18, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Jan. 17, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Jan. 17, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Jan. 13, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Jan. 12, 2023 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Jan. 3, 2023 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Dec. 22, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Dec. 21, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Dec. 21, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Dec. 15, 2022 | BOARD AND COMMITTEE CHANGES | View Document |
| 6-K | Dec. 13, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Dec. 7, 2022 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 6-K | Dec. 5, 2022 | TRANSFER OF TREASURY SHARES | View Document |
| 6-K | Dec. 2, 2022 | JEMPERLI POSITIVE TRIAL IN ENDOMETRIAL CANCER | View Document |
| 6-K | Dec. 2, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Dec. 2, 2022 | EMA FILE ACCEPTED FOR MOMELOTINIB | View Document |
| 6-K | Dec. 1, 2022 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Nov. 25, 2022 | GSK PUBLISHES PROVISIONAL 2023 DIVIDEND DATES | View Document |
| 6-K | Nov. 22, 2022 | BLENREP US UPDATE | View Document |
| 6-K | Nov. 21, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Nov. 15, 2022 | BLOCK LISTING INTERIM REVIEW | View Document |
| 3 | Nov. 14, 2022 | - | View Document |
| SC 13D/A | Nov. 14, 2022 | SCHEDULE 13D/A | View Document |
| 6-K | Nov. 14, 2022 | GSK UPDATE: ZEJULA 2L IN US | View Document |
| 6-K | Nov. 10, 2022 | SANOFI-GSK COVID BOOSTER VACCINE APPROVED BY EU | View Document |
| 6-K | Nov. 10, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Nov. 10, 2022 | BLOCK LISTING APPLICATION | View Document |
| 6-K | Nov. 7, 2022 | DREAMM-3 PHASE III TRIAL FOR BLENREP | View Document |
| SC 13D | Nov. 4, 2022 | ACQUISITION OF BENEFICIAL OWNERSHIP | View Document |
| 3 | Nov. 4, 2022 | ME - INITIAL STATEMENT OF BENEFICIAL OWNERSHIP | View Document |
| 6-K | Nov. 3, 2022 | IDMC RECOMMENDS GEPOTIDACIN EARLY EFFICACY STOP | View Document |
| 6-K | Nov. 2, 2022 | 3RD QUARTER RESULTS | View Document |
| 6-K | Nov. 2, 2022 | GSK RSV VACCINE: US FDA PRIORITY REVIEW | View Document |
| 6-K | Nov. 1, 2022 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Oct. 28, 2022 | EMA ACCEPTS GSK RSV OLDER ADULT VACCINE FOR REVIEW | View Document |
| 6-K | Oct. 28, 2022 | EMA VALIDATES MAA FOR CABOTEGRAVIR LA FOR PREP | View Document |
| 6-K | Oct. 27, 2022 | GSK ANNOUNCES FDA MEETING OUTCOME ON DAPRODUSTAT | View Document |
| 6-K | Oct. 27, 2022 | CONTRAST PHASE III PROGRAMME FOR OTILIMAB UPDATE | View Document |
| 6-K | Oct. 25, 2022 | BOARD COMMITTEE CHANGES | View Document |
| 6-K | Oct. 21, 2022 | RSV OLDER ADULT VACCINE SUBMISSION IN JAPAN | View Document |
| 6-K | Oct. 17, 2022 | MENVEO NEW SINGLE-VIAL APPROVED BY US FDA | View Document |
| 6-K | Oct. 14, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Oct. 13, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Oct. 13, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Oct. 13, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Oct. 13, 2022 | EFFICACY RESULTS FOR GSK'S OLDER ADULT RSV VACCINE | View Document |
| 6-K | Oct. 12, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Oct. 11, 2022 | US FDA APPROVES BOOSTRIX MATERNAL IMMUNISATION | View Document |
| 6-K | Oct. 7, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Oct. 7, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Oct. 3, 2022 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Sept. 30, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Sept. 26, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Sept. 26, 2022 | GSK CHIEF FINANCIAL OFFICER SUCCESSION | View Document |
| 6-K | Sept. 22, 2022 | US FDA ODAC REVIEW OF ZEJULA PHASE III NOVA TRIAL | View Document |
| 6-K | Sept. 22, 2022 | GSK AND SPERO THERAPEUTICS LICENCE FOR TEBIPENEM | View Document |
| 6-K | Sept. 21, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 4 | Sept. 20, 2022 | - | View Document |
| SC 13D/A | Sept. 20, 2022 | AMENDMENT TO FORM SC 13D | View Document |
| 25-NSE | Sept. 15, 2022 | - | View Document |
| 6-K | Sept. 13, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Sept. 8, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Sept. 6, 2022 | GSK PROVIDES UPDATE ON FDA REVIEW OF DAPRODUSTAT | View Document |
| 25-NSE | Sept. 1, 2022 | - | View Document |
| 6-K | Sept. 1, 2022 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Aug. 24, 2022 | GSK BOARD CHANGES | View Document |
| 6-K | Aug. 22, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Aug. 17, 2022 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION UPDATE | View Document |
| 6-K | Aug. 17, 2022 | FDA NEW DRUG APPLICATION FILE ACCEPTANCE FOR MMB | View Document |
| 6-K | Aug. 16, 2022 | GSK COMPLETES ACQUISITION OF AFFINIVAX, INC. | View Document |
| 6-K | Aug. 12, 2022 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 6-K | Aug. 11, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Aug. 10, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| SC 13D/A | Aug. 3, 2022 | AMENDMENT TO FORM SC 13D | View Document |
| 6-K | Aug. 3, 2022 | CURRENT REPORT OF FOREIGN ISSUER | View Document |
| 6-K | Aug. 1, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Aug. 1, 2022 | TOTAL VOTING RIGHTS | View Document |
| 6-K | July 29, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | July 29, 2022 | GSK BOARD CHANGE | View Document |
| 6-K | July 28, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | July 27, 2022 | 2ND QUARTER RESULTS | View Document |
| SC 13D | July 27, 2022 | SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP | View Document |
| 6-K | July 22, 2022 | HOLDING(S) IN COMPANY | View Document |
| 6-K | July 22, 2022 | BOARD AND COMMITTEE CHANGES | View Document |
| 6-K | July 18, 2022 | COMPLETION OF GSK SHARE CONSOLIDATION | View Document |
| 6-K | July 18, 2022 | HALEON DEMERGER COMPLETION AND SHARE CONSOLIDATION | View Document |
| 6-K | July 12, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | July 8, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | July 8, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | July 8, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | July 8, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | July 8, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | July 6, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | July 6, 2022 | RESULT OF GENERAL MEETING | View Document |
| 6-K | July 5, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | July 5, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | July 5, 2022 | GSK DISCLOSE DISCONTINUED OPERATIONS FROM Q2 2022 | View Document |
| 6-K | July 1, 2022 | TOTAL VOTING RIGHTS | View Document |
| 6-K | July 1, 2022 | GSK COMPLETES ACQUISITION OF SIERRA ONCOLOGY | View Document |
| 6-K | June 28, 2022 | GSK FILES SHINGRIX 18+ AT RISK INDICATION IN JAPAN | View Document |
| 6-K | June 28, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 11-K | June 28, 2022 | ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE | View Document |
| 11-K | June 28, 2022 | ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE | View Document |
| 6-K | June 27, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | June 24, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | June 16, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | June 10, 2022 | POSITIVE PHASE III DATA FOR GSK'S RSV OA VACCINE | View Document |
| 6-K | June 9, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | June 7, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | June 6, 2022 | US FDA APPROVAL OF PRIORIX | View Document |
| 6-K | June 1, 2022 | DEMERGER UPDATE: SUBMISSION OF DOCUMENTS TO FCA | View Document |
| 6-K | June 1, 2022 | 6-K | View Document |
| 6-K | June 1, 2022 | DEMERGER UPDATE: PUBLICATION OF DOCUMENTS | View Document |
| 6-K | May 31, 2022 | GSK TO ACQUIRE AFFINIVAX, INC. | View Document |
| 6-K | May 31, 2022 | FURTHER APPOINTMENTS TO DESIGNATE HALEON BOARD | View Document |
| SD | May 27, 2022 | SPECIALIZED DISCLOSURE | View Document |
| 6-K | May 27, 2022 | GSK CERVARIX TWO-DOSE SCHEDULE APPROVED BY NMPA | View Document |
| 6-K | May 25, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | May 23, 2022 | FORM 6-K | View Document |
| 6-K | May 19, 2022 | IAIN MACKAY - EXTERNAL APPOINTMENT | View Document |
| 424B3 | May 17, 2022 | 424B3 | View Document |
| 424B3 | May 17, 2022 | 424B3 | View Document |
| 6-K | May 16, 2022 | CHANGE OF NAME TO GSK PLC | View Document |
| SC 13D/A | May 13, 2022 | AMENDMENT TO FORM SC 13D | View Document |
| 6-K | May 13, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | May 12, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | May 11, 2022 | BLOCK LISTING INTERIM REVIEW | View Document |
| 6-K | May 9, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 25-NSE | May 9, 2022 | - | View Document |
| F-6EF | May 6, 2022 | F-6 | View Document |
| 6-K | May 4, 2022 | RESULT OF AGM | View Document |
| 6-K | May 4, 2022 | DIRECTORATE CHANGE | View Document |
| 6-K | May 3, 2022 | TOTAL VOTING RIGHTS | View Document |
| 25-NSE | May 2, 2022 | - | View Document |
| 6-K | April 27, 2022 | 1ST QUARTER RESULTS | View Document |
| 6-K | April 26, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | April 19, 2022 | DAPRODUSTAT APPLICATION ACCEPTED FOR REVIEW BY FDA | View Document |
| 6-K | April 14, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | April 14, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | April 14, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | April 13, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| DFAN14A | April 13, 2022 | DFAN14A | View Document |
| 6-K | April 13, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | April 13, 2022 | GSK AGREES TO ACQUIRE SIERRA ONCOLOGY FOR $1.9BN | View Document |
| 6-K | April 12, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | April 12, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | April 12, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | April 12, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | April 1, 2022 | GSK - SEGMENT AND PRODUCT SALES REPORTING CHANGES | View Document |
| 6-K | April 1, 2022 | TOTAL VOTING RIGHTS | View Document |
| 6-K | March 28, 2022 | PUBLICATION OF 2022 AGM NOTICE | View Document |
| 6-K | March 24, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 24, 2022 | FDA UPDATE: CABENUVA ORAL LEAD-IN NOW OPTIONAL | View Document |
| 6-K | March 23, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 23, 2022 | ISSUANCE OF NOTES | View Document |
| 6-K | March 16, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 15, 2022 | APPOINTMENTS TO DESIGNATE HALEON BOARD | View Document |
| 6-K | March 15, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 11, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 9, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 8, 2022 | GSK ANNUAL REPORT 2021 ON FORM 20-F | View Document |
| IRANNOTICE | March 8, 2022 | IRANNOTICE | View Document |
| 20-F | March 8, 2022 | 20-F | View Document |
| 6-K | March 4, 2022 | GSK PUBLISHES ANNUAL REPORT 2021 | View Document |
| 6-K | March 1, 2022 | TOTAL VOTING RIGHTS | View Document |
| 6-K | March 1, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 1, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | March 1, 2022 | DAPRODUSTAT APPLICATION ACCEPTED FOR REVIEW BY EMA | View Document |
| 6-K | Feb. 28, 2022 | FOMR 6-K | View Document |
| 6-K | Feb. 28, 2022 | FORM 6-K | View Document |
| 6-K | Feb. 24, 2022 | CANADA APPROVAL FOR MEDICAGO GSK COVID-19 VACCINE | View Document |
| 6-K | Feb. 24, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 23, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 22, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 22, 2022 | GSK CONSUMER HEALTHCARE TO BE CALLED HALEON | View Document |
| 6-K | Feb. 18, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 18, 2022 | GSK GIVES UPDATE ON RSV MATERNAL VACCINE CANDIDATE | View Document |
| 6-K | Feb. 17, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 17, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 17, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 17, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 17, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 16, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 14, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| SC 13G | Feb. 14, 2022 | SC 13G | View Document |
| 6-K | Feb. 14, 2022 | TRANSFER OF TREASURY SHARES | View Document |
| 6-K | Feb. 11, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Feb. 11, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| SC 13D/A | Feb. 10, 2022 | AMENDMENT TO FORM SC 13D | View Document |
| SC 13G/A | Feb. 10, 2022 | AMENDMENT TO SC 13G | View Document |
| SC 13G | Feb. 10, 2022 | SCHEDULE 13G | View Document |
| SC 13G/A | Feb. 10, 2022 | AMENDMENT TO SC 13G | View Document |
| SC 13G/A | Feb. 10, 2022 | AMENDMENT TO FORM SC 13G | View Document |
| 6-K | Feb. 10, 2022 | BENLYSTA APPROVED IN CHINA FOR LUPUS NEPHRITIS | View Document |
| 6-K | Feb. 9, 2022 | FINAL RESULTS | View Document |
| 6-K | Feb. 9, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| SC 13G/A | Feb. 7, 2022 | - | View Document |
| 6-K | Feb. 7, 2022 | PUBLICATION OF FULL YEAR 2021 RESULTS | View Document |
| 6-K | Feb. 2, 2022 | GSK ANNOUNCES SETTLEMENT BETWEEN VIIV AND GILEAD | View Document |
| 6-K | Feb. 1, 2022 | FDA APPROVES VIIV HEALTHCARE'S SNDA FOR CABENUVA | View Document |
| 6-K | Feb. 1, 2022 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Jan. 26, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Jan. 20, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Jan. 19, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Jan. 19, 2022 | TONY WOOD APPOINTED CSO DESIGNATE, GSK | View Document |
| 6-K | Jan. 19, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Jan. 19, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Jan. 18, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Jan. 18, 2022 | UPDATE - GSK CONSUMER HEALTHCARE | View Document |
| 6-K | Jan. 18, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Jan. 14, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Jan. 13, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Jan. 11, 2022 | US GOVT BUYS ADDITIONAL 600,000 SOTROVIMAB DOSES | View Document |
| 6-K | Jan. 11, 2022 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Jan. 4, 2022 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Dec. 23, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Dec. 22, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Dec. 21, 2021 | VIIV HEALTHCARE ANNOUNCES FDA APPROVAL OF APRETUDE | View Document |
| 6-K | Dec. 20, 2021 | CONSUMER HEALTHCARE CHAIR DESIGNATE APPOINTED | View Document |
| 6-K | Dec. 17, 2021 | XEVUDY APPROVED IN EUROPE TO TREAT COVID-19 | View Document |
| 6-K | Dec. 15, 2021 | GSK/SANOFI COVID-19 VACCINE BOOSTER & PH3 UPDATE | View Document |
| 6-K | Dec. 13, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Dec. 13, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Dec. 7, 2021 | SOTROVIMAB RETAINS ITS ACTIVITY VS OMICRON VARIANT | View Document |
| 6-K | Dec. 7, 2021 | MEDICAGO/GSK COVID-19 VACCINE POSITIVE PH3 DATA | View Document |
| 6-K | Dec. 2, 2021 | SOTROVIMAB RETAINS ITS ACTIVITY VS OMICRON VARIANT | View Document |
| 6-K | Dec. 1, 2021 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Nov. 24, 2021 | GSK PUBLISHES PROVISIONAL 2022 DIVIDEND DATES | View Document |
| 6-K | Nov. 24, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Nov. 23, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Nov. 17, 2021 | NUCALA APPROVED IN EUROPE FOR MORE INDICATIONS | View Document |
| 6-K | Nov. 15, 2021 | BLOCK LISTING INTERIM REVIEW | View Document |
| 6-K | Nov. 12, 2021 | PHASE III IM ADMINISTRATION DATA FOR SOTROVIMAB | View Document |
| 6-K | Nov. 12, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Nov. 10, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Nov. 5, 2021 | GSK SHARES POSITIVE PHASE III DATA FOR DAPRODUSTAT | View Document |
| 6-K | Nov. 1, 2021 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Oct. 27, 2021 | DIRECTORATE CHANGE | View Document |
| 6-K | Oct. 27, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Oct. 27, 2021 | 3RD QUARTER RESULTS | View Document |
| 6-K | Oct. 15, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Oct. 14, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Oct. 14, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Oct. 13, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Oct. 12, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Oct. 12, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Oct. 12, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Oct. 12, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Oct. 12, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Oct. 1, 2021 | TOTAL VOTING RIGHTS | View Document |
| SC 13G/A | Sept. 27, 2021 | AMENDMENT TO FORM SC 13G | View Document |
| 6-K | Sept. 24, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Sept. 22, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Sept. 20, 2021 | DIRECTOR DECLARATION | View Document |
| SC 13D/A | Sept. 16, 2021 | AMENDMENT TO FORM SC 13D | View Document |
| SC 13D/A | Sept. 16, 2021 | AMENDMENT TO FORM SC 13D | View Document |
| 6-K | Sept. 13, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Sept. 9, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| UPLOAD | Sept. 8, 2021 | - | View Document |
| 6-K | Sept. 7, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Sept. 3, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Sept. 1, 2021 | TOTAL VOTING RIGHTS | View Document |
| 6-K | Aug. 31, 2021 | SK BIO & GSK START PH3 COVID-19 VACCINE TRIAL | View Document |
| CORRESP | Aug. 31, 2021 | - | View Document |
| 6-K | Aug. 25, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Aug. 23, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| UPLOAD | Aug. 18, 2021 | - | View Document |
| 6-K/A | Aug. 13, 2021 | DIRECTOR/PDMR SHAREHOLDING - AMENDMENT | View Document |
| 6-K | Aug. 11, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Aug. 11, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | Aug. 5, 2021 | BLOCK LISTING APPLICATION | View Document |
| 6-K | Aug. 2, 2021 | TOTAL VOTING RIGHTS | View Document |
| 6-K | July 28, 2021 | 2ND QUARTER RESULTS | View Document |
| 6-K | July 28, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | July 26, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | July 23, 2021 | BOARD COMMITTEE CHANGES | View Document |
| 6-K | July 22, 2021 | CEO DESIGNATE OF NEW CONSUMER HEALTHCARE COMPANY | View Document |
| 6-K | July 16, 2021 | GSK ANNOUNCES DAPRODUSTAT PHASE 3 HEADLINE RESULTS | View Document |
| 6-K | July 16, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | July 15, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | July 14, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | July 14, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | July 13, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | July 13, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| SC 13G | July 12, 2021 | SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP | View Document |
| 6-K | July 12, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | July 12, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | July 9, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 4 | July 6, 2021 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP | View Document |
| 3 | July 6, 2021 | INITIAL STATEMENT OF BENEFICIAL OWNERSHIP | View Document |
| 6-K | July 2, 2021 | ELLIOTT ADVISORS (UK) LETTER TO GSK | View Document |
| 6-K | July 2, 2021 | GSK AND ALECTOR COLLABORATION IN IMMUNO-NEUROLOGY | View Document |
| 6-K | July 1, 2021 | TOTAL VOTING RIGHTS | View Document |
| 6-K | June 25, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 11-K | June 25, 2021 | ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE | View Document |
| 11-K | June 25, 2021 | ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE | View Document |
| 6-K | June 24, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | June 23, 2021 | GSK TO DELIVER STEP-CHANGE IN GROWTH & PERFORMANCE | View Document |
| 4 | June 23, 2021 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | View Document |
| 6-K | June 22, 2021 | VIIV/HALOZYME SIGN EXCLUSIVE LICENSING AGREEMENT | View Document |
| 3 | June 17, 2021 | INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES | View Document |
| 6-K | June 14, 2021 | GSK AND ITEOS ANNOUNCE COLLABORATION FOR EOS-448 | View Document |
| 6-K | June 11, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | June 9, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | June 4, 2021 | TRC CAPITAL LETTER | View Document |
| 6-K | June 1, 2021 | TOTAL VOTING RIGHTS | View Document |
| 6-K | May 27, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | May 27, 2021 | SANOFI AND GSK INITIATE NEW PHASE 3 CLINICAL STUDY | View Document |
| 6-K | May 27, 2021 | GSK/VIR SOTROVIMAB FDA EMERGENCY USE AUTHORIZATION | View Document |
| SD | May 27, 2021 | SD | View Document |
| SC 13D/A | May 25, 2021 | AMENDED SCHEDULE 13D | View Document |
| 4 | May 24, 2021 | CHANGES IN BENEFICIAL OWNERSHIP | View Document |
| 6-K | May 24, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 6-K | May 21, 2021 | GSK/VIR SOTROVIMAB RECEIVES POSITIVE EMA OPINION | View Document |
| 6-K | May 18, 2021 | MEDICAGO/GSK COVID-19 VACCINE POSITIVE PH2 RESULTS | View Document |
| 6-K | May 18, 2021 | BLOCK LISTING INTERIM REVIEW | View Document |
| 6-K | May 17, 2021 | SANOFI/GSK COVID-19 VACCINE POSITIVE PH2 RESULTS | View Document |
| 25-NSE | May 14, 2021 | - | View Document |
| 6-K | May 13, 2021 | DIRECTOR/PDMR SHAREHOLDING | View Document |